Patients with melanoma brain metastases respond to immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors (BRAF/MEKi); however, they are underrepresented in clinical trials [2,3,4]. The gene discussed is MAP2K7; the disease is melanoma.